BMS Accelerates Cobenfy 125 mg Dosing; Eyes Sotyktu TYK2 Lupus Readouts in Q2 2026

Update: Cobenfy titration education toward 125 mg and impact on sales; confidence in Sotyktu’s TYK2 mechanism for lupus ahead of readouts

1) Cobenfy dosing education: what BMS is doing and what it means for titration to 125 mg

BMS indicates that, in schizophrenia, a key commercial drag has been clinicians “not titrating up quickly enough to the therapeutic dose,” and that the company is now educating physicians on rapidly titrating Cobenfy to 125 mg because BMS “see[s] far too many patients that remain on either the 50 or 100-milligram dose.” ¹

BMS also quantifies progress from an operational change: the company reports an increase in 125 mg prescribing after introducing its Phase IV switch study, which it says “will both help maximize efficacy,” but also concedes it “need[s] to see further increases in the dose shift towards the 125 milligrams.” ¹

How this ties to the sales trajectory (what management is signaling)

BMS frames dosing optimization as part of a broader set of leading indicators and execution goals:

• The company reports “positive leading indicators” including ~15% TRx growth quarter-over-quarter in the quarter. ¹
• It states that despite progress, “we need to make further progress” on accelerating new patient starts and improving repeat prescribing, noting that prescribing behavior is “deeply entrenched.” ¹
• On dosing specifically, BMS implies the sales impact would emerge as the market shifts from 50/100 mg to 125 mg; they say they need “further increases in the dose shift” even while confidence improves via the Phase IV switch study. ¹

Net interpretation: BMS’s messaging suggests that the next step-change in Cobenfy sales performance is likely to come from (1) more patients being started and continued, and (2) completion of the dose-shift to 125 mg—i.e., education is necessary but not sufficient, because repeat prescribing and starts are also highlighted as remaining gaps. ¹

Observed business performance for context

In the quarter, BMS reports Cobenfy revenue of $63 million and 81% growth (year-over-year growth rate in the quarter as presented in the call materials). ² This provides a baseline that growth is occurring even as BMS still targets further dose-shift improvements. ¹²

2) Impact on sales: timing expectations BMS provides (and what is not claimed)

In the excerpt, BMS does not provide a specific month/quarter forecast for when the 125 mg education-driven shift will show up in sales. ³¹ Instead, it gives qualitative expectations:

• It says it has “a meaningful opportunity to continue to build confidence and bring clarity on how to maximize Cobenfy use.” ¹
• It also states it “do[es] expect Cobenfy to grow consistently throughout the year,” and points to “significant upside through a very broad LCM program.” ¹

So the sales impact linkage is directional rather than calendared: education and the Phase IV switch study are already increasing 125 mg prescribing, and BMS expects ongoing growth, but the excerpt does not quantify what portion of growth is attributable to dosing versus starts/repeat prescribing. ¹

3) Sotyktu in lupus (SLE): confidence in the TYK2 mechanism and what BMS says about upcoming readouts

Confidence grounded in clinical evidence (Phase II) and differentiation thesis

BMS ties its SLE readout expectations to a Phase II SLE study outcome:

• BMS says the Phase II study “met both the primary and key secondary efficacy endpoints,” and that it is “one of the largest and most compelling in SLE to date.” ⁴
• Management states this gives it “a lot of confidence” and a “real opportunity to differentiate Sotyktu based on overall clinical responses,” including “the ability to reduce steroid dependence” and “also associated toxicity.” ⁴
• BMS also characterizes the upcoming SLE data readout as a potential growth catalyst: “we very much look forward to our SLE data readout this year as this could really catalyze growth for the brand.” ⁴

Mechanism-of-action confidence (TYK2) and lupus-readout context

Your question asks specifically about confidence in Sotyktu’s TYK2 mechanism for lupus given upcoming readouts. In the excerpt, management’s confidence appears to be expressed primarily through the Phase II SLE results and the expectation that SLE readouts can “catalyze growth.” ⁴

Separately, BMS’s commentary on trial success emphasizes that confidence is also supported by execution and endpoint management: BMS notes that the Phase II success is “not very typical” in this space and credits “checking carefully steroid tapering and actively monitoring the primary endpoint.” ⁵ This reinforces confidence in the clinical translation in lupus rather than a mechanistic argument alone. ⁵

Upcoming readouts timing and what to expect from management’s framing

BMS frames the lupus readout sequencing as:

• SLE readout “this year” and Sjogren’s readout “next year.” ¹
• The company also explicitly looks forward to the SLE readout as a “catalyze growth” event for Sotyktu. ⁴¹

Net interpretation: Based on the excerpts, BMS’s confidence in TYK2 for lupus is expressed through clinical performance and study integrity (Phase II meeting endpoints; ability to reduce steroid dependence and toxicity; and mirroring Phase II into later programs), with management expecting meaningful commercial momentum from the SLE readout this year. ⁴⁵

Bottom line

• Cobenfy (125 mg titration): BMS is actively addressing a known dosing-optimization drag by educating physicians to rapidly titrate to 125 mg, noting too many remain at 50 or 100 mg. ¹ Prescribing of 125 mg has increased since the Phase IV switch study, but BMS still expects additional dose-shift progress beyond that improvement. ¹ Sales are already growing strongly (Cobenfy revenue $63 million; 81% growth), while BMS highlights remaining needs in new patient starts and repeat prescribing as additional determinants of the sales trajectory. ¹²
• Sotyktu (TYK2 in lupus): BMS reports high confidence based on a Phase II SLE study that met primary and key secondary endpoints, with a differentiation thesis around overall responses, reduced steroid dependence, and toxicity—plus an expectation that the SLE readout this year could catalyze growth. ⁴ BMS also emphasizes that Phase III efforts are “mimic[king] the Phase II study” in a way management considers aligned in demographics, design, and endpoints. ⁵